Browse studies

Find your next paid study

25,453 recruiting studies available now

A Randomized, Double-blind, Placebo-controlled Trial of ALTO-207 in Adults With Treatment-resistant Depression

The purpose of this trial is to measure depressive symptoms following treatment with ALTO-207 compared with placebo in participants with TRD.

Treatment-resistant Depression (TRD)

Estimated

~$75 – $3,000

Actual pay is set by the research site.

Alto NeuroscienceNCT07553637

Phase 2

Adaptive Modification of Neoadjuvant Therapy Based on Clinical Response in Patients With Localized Pancreatic Cancer

This is an open-label, phase II study in patients with resectable and borderline resectable pancreas cancer.

Pancreatic Cancer

Estimated

~$75 – $2,000

Actual pay is set by the research site.

Medical College of WisconsinNCT03322995

Phase 1

A Study to Explore Changes in Cognitive, Clinical, Biological and Digital Measures Following 8 Weeks of Twice-daily Dosing of MT1988 and to Evaluate Safety & Tolerability of MT1988, in Participants at Clinical High Risk (CHR) for Psychosis

The goal of this clinical trial is to learn how tests undertaken by people at high risk of developing psychosis (aged 17 to 30 years old) change when those peo…

Clinical High Risk for Psychosis (CHR)

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Monument Therapeutics LimitedNCT07226895

Genomic Analysis of Families With a History of Discordant Cancers

The purpose of this study is to identify novel gene mutations which have contributed to significant personal and family history of cancer. Adults with and with…

Discordant Cancers

Estimated

~$10 – $750

Actual pay is set by the research site.

Case Comprehensive Cancer CenterNCT04860453

Phase 1

A Phase 1a/1b, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of IMGS-001 in Patients With Relapsed or Refractory Advanced Solid Tumors

The purpose of this Phase 1a/1b clinical trial is to test the safety of an investigational drug called IMGS-001 and to determine how well it can work in treati…

Solid Tumor

Estimated

~$150 – $4,500

Actual pay is set by the research site.

ImmunoGenesisNCT06014502

Observational

Investigating the Benefits of Remotely-Supervised Neuromodulation In Primary Progressive Aphasia

The goal of this clinical trial is to learn whether home-based brain stimulation combined with virtual speech-language therapy can improve communication abilit…

Primary Progressive Aphasia(PPA)Progressive AphasiaProgressive Aphasia in Alzheimer's Disease+3 more

Estimated

~$10 – $1,125

Actual pay is set by the research site.

Maya HenryNCT07260253

Phase 1

A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of the IKS04 Regimen Targeting CA242

This study will evaluate the safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of the IKS04 Regimen and identify…

Colorectal CancerGastro Esophageal Junctional CancerGastric Cancer (GC)+5 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Iksuda Therapeutics Ltd.NCT07738939

Phase 1

A Phase IB, Single Dose, Open-Label, Dose-escalation Study to Investigate the Safety and Imaging Characteristics of Pemefolacianine for Intraoperative Molecular Imaging of Lung Cancer

The aim of this Phase 1b study is to investigate the safety and fluorescence signal of a single dose of Pemefolacianine for Injection, a novel fluorescence ima…

Lung Cancer (Locally Advanced or Metastatic)

Estimated

~$150 – $4,500

Actual pay is set by the research site.

Sunil SinghalNCT07772895

Non-interventional Cohort Study of Patients Treated With Liso-cel (Lisocabtagene Maraleucel) for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in the Post-Marketing Setting

The purpose of this study is to characterize the long-term safety of lisocabtagene maraleucel (liso-cel), focusing on patients treated in the chronic lymphocyt…

Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)

Estimated

Pay not disclosed — ask the coordinator

Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyNCT06788639

Phase 1

A Phase I Study of Hyper-CVAD In Combination With Venetoclax In Pediatric Patients With Relapsed or Refractory Acute Leukemias That Are of the Lymphoid Lineage Including Bi-Phenotypic or Undifferentiated Leukemias

To find the recommended dose of hyper-CVAD in combination with venetoclax that can be given to participants with relapsed or refractory leukemia.

Refractory Acute LeukemiaRelapsed Acute LeukemiaUndifferentiated Leukemia+1 more

Estimated

~$150 – $3,000

Actual pay is set by the research site.

M.D. Anderson Cancer CenterNCT06466395

Observational

Chronic Treatment of Alzheimer's Disease With Gamma Frequency Stimulation

Alzheimer's disease (AD) is characterized by significant memory loss, toxic protein deposits amyloid and tau) in the brain, and changes in the gamma frequency …

Alzheimer DiseaseAlzheimer Disease, Early OnsetAlzheimer Disease, Late Onset+3 more

Estimated

~$10 – $750

Actual pay is set by the research site.

Massachusetts Institute of TechnologyNCT05655195

Phase 3

A Phase 3, Single-Arm, Open-Label Extension Study Evaluating the Long-Term Safety and Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy

The purpose of this study is to evaluate the long-term safety, tolerability and efficacy of povetacicept in participants with immunoglobulin A nephropathy (IgA…

Immunoglobulin A Nephropathy

Estimated

~$50 – $2,100

Actual pay is set by the research site.

Vertex Pharmaceuticals IncorporatedNCT07807995